Four-factor prothrombin complex concentrate versus andexanet alfa for the reversal of traumatic brain injuries
Emergency Medicine Journal
FEBRUARY 20, 2024
Primary outcome includes rate of mortality/hospice at hospital discharge. After adjusting for severity of TBI and comorbidities with regard to tomortality/hospice, there were 15 (25.4%) patients in the andexanet alfa group and 49 (18.5%) in the 4F-PCC group (OR 1.34; 95% CI 0.67 vs 26.1%; p<0.005).
Let's personalize your content